Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)

Phase 2

Completed

Conditions: Lung Cancer
Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Ipilimumab
Drug: Placebo
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2007-09-11

Last Posted Date: 2018-07-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 334

Registration Number: NCT00527735

Locations: 🇺🇸
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
🇺🇸
Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States
🇺🇦
Local Institution, Uzhgorod, Ukraine

and more 22 locations

Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Dietary Supplement: selenomethionine
Drug: carboplatin
Drug: paclitaxel
Other: laboratory biomarker analysis
Radiation: radiation therapy

First Posted Date: 2007-09-10

Last Posted Date: 2017-11-28

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT00526890

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.

Phase 2

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Trastuzumab
Drug: Paclitaxel
Drug: FEC75
Drug: Lapatinib

First Posted Date: 2007-09-03

Last Posted Date: 2016-11-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 100

Registration Number: NCT00524303

Locations: 🇺🇸
GSK Investigational Site, Yakima, Washington, United States

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Phase 3

Terminated

Conditions: Melanoma

Interventions: Drug: Elesclomol (STA-4783)
Drug: Paclitaxel

First Posted Date: 2007-08-30

Last Posted Date: 2014-03-04

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 630

Registration Number: NCT00522834

Locations: 🇺🇸
The Ohio State University., Columbus, Ohio, United States
🇺🇸
Cancer Pavilion, Pittsburgh, Pennsylvania, United States
🇺🇸
University of California San Diego Moores UCSD Cancer Center, La Jolla, California, United States

and more 96 locations

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Phase 3

Terminated

Conditions: Recurrent Breast Carcinoma
Stage IV Breast Cancer
Breast Carcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel
Other: Placebo
Biological: Trastuzumab

First Posted Date: 2007-08-27

Last Posted Date: 2017-02-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00520975

Locations: 🇺🇸
Galesburg Cottage Hospital, Galesburg, Illinois, United States
🇺🇸
Fredericksburg Oncology Inc, Fredericksburg, Virginia, United States
🇺🇸
Wayne Hospital, Greenville, Ohio, United States

and more 370 locations

Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
Papillary Serous Mullerian Tumor
Clear Cell Mullerian Tumor

Interventions: Drug: bevacizumab
Drug: paclitaxel
Drug: erlotinib
Drug: carboplatin

First Posted Date: 2007-08-23

Last Posted Date: 2018-07-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00520013

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Neoplasms

First Posted Date: 2007-08-17

Last Posted Date: 2011-02-25

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 100

Registration Number: NCT00517621

Locations: 🇫🇷
HOTEL DIEU Hospital, Paris, France

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Phase 1

Completed

Conditions: Carboplatin
Triple Negative Metastatic Breast Cancer
Advanced Ovarian Cancer
Paclitaxel

Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Drug: Carboplatin
Drug: Paclitaxel
Drug: Paclitaxel + Carboplatin

First Posted Date: 2007-08-15

Last Posted Date: 2024-05-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 189

Registration Number: NCT00516724

Locations: 🇬🇧
Research Site, London, United Kingdom

Papillary Serous Carcinoma of the Endometrium

Phase 2

Completed

Conditions: Endometrial Cancer

Interventions: Drug: Paclitaxel
Radiation: Pelvic Radiation
Drug: Dexamethasone
Drug: Cimetidine
Drug: Diphenhydramine

First Posted Date: 2007-08-13

Last Posted Date: 2014-07-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00515073

Locations: 🇺🇸
M. D. Anderson Cancer Center - Orlando, Orlando, Florida, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2

Completed

Conditions: Stage II Breast Cancer
Inflammatory Breast Cancer
Male Breast Cancer
Stage IIIC Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: sunitinib malate
Drug: paclitaxel
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: filgrastim
Procedure: therapeutic conventional surgery
Other: laboratory biomarker analysis
Other: flow cytometry

First Posted Date: 2007-08-09

Last Posted Date: 2019-08-07

Lead Sponsor: University of Washington

Target Recruit Count: 68

Registration Number: NCT00513695

Locations: 🇺🇸
Skagit Valley Hospital, Mount Vernon, Washington, United States
🇺🇸
Olympic Medical Center, Port Angeles, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy